Physiology

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

Retrieved on: 
Wednesday, April 10, 2024

To propel organoid research, drug discovery, and therapeutic advancements, ACROBiosystems presents the Organoid Toolbox, the comprehensive suite of solutions designed to unlock the potential of organoids across diverse applications.

Key Points: 
  • To propel organoid research, drug discovery, and therapeutic advancements, ACROBiosystems presents the Organoid Toolbox, the comprehensive suite of solutions designed to unlock the potential of organoids across diverse applications.
  • This encompasses ready-to-use organoids, organoid differentiation kits, cytokines for organoid culture, matrix materials for organoid cultivation, organoid differentiation services, and compound testing services on organoids.
  • By leveraging its proprietary organoid research and development platform, the company is seeking to continuously expand its solutions by creating organoids like retina, skin, and lung; thereby broadening the scope of organoid applications.
  • Through advanced in-house organoid differentiation and cryopreservation technologies, ACROBiosystems has achieved pivotal breakthroughs in organoids with conventionally challenging differentiation processes and long maturation periods, delivering highly efficient and user-friendly organoid solutions globally.

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

Retrieved on: 
Wednesday, April 10, 2024

HOUSTON, April 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced positive preclinical data regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego, CA.

Key Points: 
  • The poster titled, Non-cardiotoxic Properties of Annamycin, a Clinically Evaluated Anthracycline and Potent Topoisomerase 2β Poison , was presented in the "Late-Breaking Research: Experimental and Molecular Therapeutics 2" session held on Monday, April 8th.
  • These data, documenting lack of cardiotoxicity of Annamycin and aligned with the data demonstrated to date in our ongoing clinical trials, bolster our confidence in Annamycin potential to offer patients a safe and effective treatment option.
  • Annamycin and doxorubicin cytotoxicity was assessed in a panel of cancer cell lines cardiomyocytes (murine and human).
  • For more information about the ongoing trials, please visit clinicaltrialsregister.eu : EudraCT 2020-005493-10 or clinicaltrials.gov : NCT05319587; and clinicaltrials.gov : NCT04887298, respectively.

Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections

Retrieved on: 
Wednesday, April 10, 2024

Once developed, Inspira plans to integrate the bio-electronic novel physical stimulation technology, into the INSPIRA™ ART patient treatment.

Key Points: 
  • Once developed, Inspira plans to integrate the bio-electronic novel physical stimulation technology, into the INSPIRA™ ART patient treatment.
  • The results of the in vitro study showed a 75% reduction in bacterial growth 4 hours after the application of the treatment and a 100% reduction within 24 hours.
  • The in vitro study was carried out at the Hebrew University of Jerusalem and involved testing bioelectric patches in an in vitro environment.
  • As part of the in vitro study, bacteria were cultured and spread on agar in petri dishes.

The weather experiment that really flooded Dubai

Retrieved on: 
Thursday, April 25, 2024

That was the story last week when more than a year’s worth of rain fell in a day on the Arabian Peninsula, one of the world’s driest regions.

Key Points: 
  • That was the story last week when more than a year’s worth of rain fell in a day on the Arabian Peninsula, one of the world’s driest regions.
  • Desert cities like Dubai in the United Arab Emirates (UAE) suffered floods that submerged motorways and airport runways.
  • Every Wednesday, The Conversation’s environment editor writes Imagine, a short email that goes a little deeper into just one climate issue.
  • Richard Washington, a professor of climate science at the University of Oxford, has seen the inside of a storm.
  • To confirm if cloud seeding really could breed record-breaking rain, he once boarded an aeroplane bound for a thundercloud over the South Africa-Mozambique border.

What caused the flood?

  • But by flying a lot of missions, half with cloud seeding and half without, and measuring rainfall between the two, meteorologists eventually showed that cloud seeding did modify rain rates in some storms.
  • That’s not what caused Dubai’s floods though.
  • Their approach is to fire hygroscopic (water-attracting) salt flares from aircraft into warm cumuliform clouds,” Washington says.
  • “So could seeding have built a huge storm system the size of France?
  • Let’s be clear, that would be like a breeze stopping an intercity train going at full tilt.

The experiment of our lives

  • Although last week’s deluge was unusual, the Arabian Peninsula does tend to receive more of its precipitation in heavy bursts than steady showers.
  • What is likely to kill more people as temperatures rise in this part of the world is not water, but heat.
  • At this threshold the air is so hot and humid that you cannot lower your temperature to a safe level by sweating.
  • Peter Irvine, a lecturer in earth sciences at UCL, proposes dimming the sun by pumping microscopic particles into the upper atmosphere to reflect some of its rays.
  • These layers of gases that surround our planet have nurtured life by keeping temperatures stable and harmful radiation out.
  • Read more:
    Time is running out on climate change, but geoengineering has dangers of its own

    As humanity contemplates another large-scale experiment in our atmosphere, there is another, even bigger one, waiting to be resolved.

Drinking apple cider vinegar may help with weight loss but its health benefits are overstated

Retrieved on: 
Wednesday, April 10, 2024

One day, she explained that she adds apple cider vinegar to improve my health.

Key Points: 
  • One day, she explained that she adds apple cider vinegar to improve my health.
  • Apple cider vinegar is a natural product made of fermented apple juice that has gone sour.
  • I decided to turn medical sleuth and investigate whether apple cider vinegar is as good for health as it sounds.

Claim: disinfectant properties

  • But does apple cider vinegar’s decontaminant qualities translate to the human gut?
  • Our stomachs produce acid, which acts as a natural barrier to infection, so how can adding more acid help?

Claim: weight loss and management of type 2 diabetes

  • There are plenty of anecdotal claims that apple cider vinegar can aid weight loss, supported by limited evidence from several small studies.
  • Apple cider vinegar is thought to cause weight loss through its effect on delay of gastric emptying.
  • Reduced calorific intake will lead to weight loss – but how are the metabolic effects on blood glucose and lipids mediated?
  • In type 2 diabetes there is a reduction in sensitivity to insulin which in turn leads to a reduced uptake of glucose by cells.

Claim: reduces risk of heart disease

  • Raised blood lipids are a risk factor for cardiovascular diseases such as myocardial infarction and stroke.
  • Well, I’m afraid there’s no scientific evidence that vinegar consumption of any kind reduces cardiovascular morbidity and mortality in those with or without diabetes.

Claim: cancer treatment and prevention

  • One of the more outrageous claims of benefits of daily apple cider vinegar consumption is that it may prevent or treat cancer.
  • A frequently quoted case-control study from China found that an increased consumption of vinegar was associated with a reduced incidence of oesophageal cancer.


Stephen Hughes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Retrieved on: 
Tuesday, April 9, 2024

We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).

Key Points: 
  • We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).
  • Our CEO has agreed to further defer a considerable portion of his accrued compensation, affirming the belief in Chromocell’s mission.
  • We truly feel that our IPO and recent therapeutic development activities have positioned Chromocell for long term growth and success.
  • I wish to thank you for your support and remain a resource to each of you as we move forward.

HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease

Retrieved on: 
Tuesday, March 26, 2024

The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronary artery disease (CAD).

Key Points: 
  • The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronary artery disease (CAD).
  • The DECODE study showed that clinicians using the HeartFlow Plaque Analysis changed their management decisions for 66% of patients compared to CCTA alone across various patient presentations and disease stages.
  • “We believe real-world prospective data from the new DECIDE Registry will empower clinicians with enhanced patient insights leveraging HeartFlow Plaque Analysis to improve patient outcomes.
  • The primary endpoint for this registry will highlight change in medical management after HeartFlow Plaque Analysis compared to after CCTA alone.

Premium Jane Introduces Innovative Keto Product Line to Enhance Ketogenic Diet Experience

Retrieved on: 
Monday, April 8, 2024

The cornerstone of Premium Jane's new Keto line is a once-a-day fiber supplement formulated with inulin and chicory root - two crucial (but often overlooked) components of the ketogenic diet.

Key Points: 
  • The cornerstone of Premium Jane's new Keto line is a once-a-day fiber supplement formulated with inulin and chicory root - two crucial (but often overlooked) components of the ketogenic diet.
  • "We are beyond thrilled to unveil our new Keto product line," says Premium Jane CEO Jeff Yauck.
  • Additionally, Premium Jane is offering Keto BHB gummies, which contain a unique blend of calcium, magnesium, and sodium beta-hydroxybutyrate (BHB).
  • To place an order or to learn more about the new Keto product range from Premium Jane, visit the company's official website at www.PremiumJane.com .

Parker University Announces the Accreditation of its Master of Science in Strength and Human Performance Program

Retrieved on: 
Monday, March 25, 2024

Parker University is proud to announce that its graduate-level Strength and Conditioning program has been granted five years of initial accreditation status!

Key Points: 
  • Parker University is proud to announce that its graduate-level Strength and Conditioning program has been granted five years of initial accreditation status!
  • Parker University’s Strength and Human Performance Program Director Jenna Romanelli, MS, Med, RD, CSC, says, “The CASCE accreditation directly reflects our Strength and Human Performance degree.
  • Parker University’s degrees in Strength and Human Performance provide students with an expansive study of evidence-based research in physiology, biomechanics, and human metabolism to enhance health, function, and physical performance.
  • Parker University is proud of its unwavering dedication to providing strength and conditioning education of the highest quality.

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Retrieved on: 
Friday, March 22, 2024

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.

Key Points: 
  • Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.
  • Tear Film Break-up Time showed statistically significant improvement as early as day 15 with the benefit durable for the remainder of the trial.
  • Burning/Stinging, and Blurred Vision improved as early as day 15 and the benefit remained durable throughout the trial.
  • Significant improvements were observed across multiple symptoms as measured in a daily symptom diary including pain, burning/stinging, eye dryness and itching within the first two weeks of treatment.